I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C., 20231, on:

Date: Mysst 20, 2001

Docket No. 4600-0183.26

By: Jellinger Maher

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

Reyes, et al.N

SERIAL No.: 09/851,410

FILED: May 7, 2001

FOR: DNA SEQUENCES OF ENTERICALLY

TRANSMITTED NON-A/NON-B HEPATITIS VIRAL AGENT Examiner: Unkn

Unknown

ART UNIT:

Unknown

<u>Information Disclosure Statement Within Three Months of</u> Application Filing or Before First Action - 37 CFR 1.97(b)

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

1. Timing of Submission

This information disclosure is being filed within three months of the filing date of this application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever occurs last [37 CFR 1.97(b)]. The references listed on the enclosed Form PTO-1449 (modified) may be material to the examination of this application; the Examiner is requested to make them of record in the application.

2. Cited Information

Ź	Copie	s of the following references are enclosed:
		All cited references
		References marked by asterisks
		The following:

- □ Copies of the following references can be found in parent application Ser. No. 09/128,275:

 - ☐ References marked by asterisks
 - The following:

1

USSN: 09/851,410

3. Effect of Information Disclosure Statement (37 CFR 1.97(h)

This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

4. Fee Payment

No fees are believed due. However, should the Commissioner determine that fees are due in order for this Information Disclosure Statement to be considered, the Commissioner is hereby authorized to charge such fees to Deposit Account No. 50-0665.

Respectfully submitted,

Larry W. Thrower

Registration No. 47,994

Correspondence Address:

Customer No. 22918

Date: 8-20-01

INFORMATION DISCLOSURE CITATION

Form PTO-1449 (Modified)

several sheets if necessary)

ATTY. DOCKET NO. 4600-0183.26

SERIAL NO.

09/851,410

APPLICANT

Reyes, et al.

FILING DATE

GROUP

May 7, 2001

Unknown

U.S. PATENT DOCUMENTS

	T 5	Date	Name	Class	Subclass	Filing Date
Examiner	Document	Date	Name	CIASS	Duperass	· ~
Initial	Number					If Appropriate
	4,659,67	04/21/87	Forrest et al.			
	4,683,195	07/28/87	Mullis et al.			
	4,871,659	10/03/89	Pillot			
	5,077,193	12/31/91	Pillot			
	5,789,559	08/04/98	Reyes et al.			

FOREIGN PATENT DOCUMENTS

	Document	Date	Country	Class	Subclass	Translation
		Date	Journal 1	1		
	Number			·		
V	85/01517	04/11/85	WO			
	88/03410	05/19/88	WO			
	89/12641	12/28/89	WO			
	2 606 515	05/19/88	FR			
	2 609 807	06/22/88	FR			

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

1	Lewin, R., "When Does Homology Mean Something Else?," Science, 237:1570 (1987).
	New England Bio Labs 1988-1989 Catalog, p. 62.
	Sambrook, J., et al., Molecular Cloning, A Laboratory Manual,
1	Volume 2, Cold Spring Harbor Laboratory Press, Cold Spring Harbor,
	New York, pp. 8.46-8.49, 11.11-11.57 (1989).
	Sambrook, J., et al., Molecular Cloning, A Laboratory Manual,
1	Volume 2, Cold Spring Harbor Laboratory Press, Cold Spring Harbor,
	New York, pp. B.20 (1989).
h — — — I i i	Sarthou, J.I., et al., "Characterization of an Antigen-Antibody
	System Associated with Epidemic Non-A, Non-B Hepatitis in West
	Africa and Experimental Transmission of an Infectious Agent to

	Primates," A.m. Inst. Pasteur/Virol., 137(F): 225-232 (1986).
	Sigma Chemical Company, "Sigma Price List 1987," p. 1024 (1987).
EXAMINER	DATE CONSIDERED
609; Draw lir	nitial if reference considered, whether or not citation is in conformance with MPEF e through citation if not in conformance and not considered. Include copy of this t communication to applicant.